JP2004527551A5 - - Google Patents

Download PDF

Info

Publication number
JP2004527551A5
JP2004527551A5 JP2002584912A JP2002584912A JP2004527551A5 JP 2004527551 A5 JP2004527551 A5 JP 2004527551A5 JP 2002584912 A JP2002584912 A JP 2002584912A JP 2002584912 A JP2002584912 A JP 2002584912A JP 2004527551 A5 JP2004527551 A5 JP 2004527551A5
Authority
JP
Japan
Prior art keywords
escitalopram
citalopram
placebo
treatment
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002584912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004527551A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2002/000281 external-priority patent/WO2002087566A1/en
Publication of JP2004527551A publication Critical patent/JP2004527551A/ja
Publication of JP2004527551A5 publication Critical patent/JP2004527551A5/ja
Pending legal-status Critical Current

Links

JP2002584912A 2001-05-01 2002-05-01 エナンチオ純粋なエスシタロプラムの使用方法 Pending JP2004527551A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100684 2001-05-01
PCT/DK2002/000281 WO2002087566A1 (en) 2001-05-01 2002-05-01 The use of enantiomeric pure escitalopram

Publications (2)

Publication Number Publication Date
JP2004527551A JP2004527551A (ja) 2004-09-09
JP2004527551A5 true JP2004527551A5 (https=) 2009-08-13

Family

ID=8160464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002584912A Pending JP2004527551A (ja) 2001-05-01 2002-05-01 エナンチオ純粋なエスシタロプラムの使用方法

Country Status (25)

Country Link
US (7) US20040198809A1 (https=)
EP (1) EP1385503A1 (https=)
JP (1) JP2004527551A (https=)
KR (2) KR20100012089A (https=)
CN (1) CN1509169A (https=)
AR (1) AR033308A1 (https=)
AT (1) AT10974U1 (https=)
BG (1) BG108379A (https=)
BR (1) BR0208283A (https=)
CA (1) CA2445843A1 (https=)
CZ (1) CZ20033267A3 (https=)
EA (1) EA200301195A1 (https=)
HR (1) HRP20030744A2 (https=)
HU (1) HUP0400054A3 (https=)
IL (1) IL158031A0 (https=)
IS (1) IS6954A (https=)
ME (1) MEP5908A (https=)
MX (1) MXPA03008777A (https=)
NO (1) NO20034538D0 (https=)
PL (1) PL367480A1 (https=)
SK (1) SK14612003A3 (https=)
UA (1) UA82828C2 (https=)
WO (1) WO2002087566A1 (https=)
YU (1) YU85303A (https=)
ZA (1) ZA200307102B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
AU2003287919B2 (en) * 2002-12-23 2009-11-12 H. Lundbeck A/S Escitalopram hydrobromide and a method for the preparation thereof
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
PL1691811T3 (pl) * 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
WO2005084643A1 (en) * 2004-03-05 2005-09-15 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
TWI347942B (en) * 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
EA200801081A1 (ru) 2005-10-14 2008-10-30 Х. Лундбекк А/С Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
JP2009511607A (ja) * 2005-10-14 2009-03-19 ハー・ルンドベック・アクチエゼルスカベット エスシタロプラムおよびブプロピオンを含有する安定な医薬製剤
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
CN100353939C (zh) * 2006-01-05 2007-12-12 昆明积大制药有限公司 含西酞普兰和环糊精的抗抑郁口服药用组合物
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
CA2672925A1 (en) * 2006-10-20 2008-04-24 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
US20100003313A1 (en) * 2006-10-27 2010-01-07 Hisamitsu Pharmaceutical Co.,Inc. Adhesive skin patch
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
US20090036468A1 (en) * 2007-08-03 2009-02-05 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
SG185969A1 (en) * 2008-01-31 2012-12-28 Takeda Pharmaceutical Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder
ITMI20080768A1 (it) * 2008-04-24 2009-10-25 Abiogen Pharma Spa Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one
JP5740300B2 (ja) * 2009-02-27 2015-06-24 久光製薬株式会社 経皮投与製剤
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
US10702512B2 (en) * 2015-05-13 2020-07-07 A. Carlsson Research Ab Treatment of debilitating fatigue

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (https=) * 1965-03-18
US4079135A (en) * 1973-12-13 1978-03-14 Imperial Chemical Industries Limited Morpholine derivatives as antidepressants
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
EA002770B1 (ru) * 1997-11-11 2002-08-29 Х.Лундбекк А/С Способ получения циталопрама
AU4850199A (en) * 1998-06-30 2000-01-17 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
PL199423B1 (pl) * 1998-10-20 2008-09-30 Lundbeck & Co As H Sposób wytwarzania citalopramu
DK1173431T4 (da) * 1999-04-14 2010-01-04 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US6469064B2 (en) * 2000-04-24 2002-10-22 Aryx Therapeutics Materials and methods for the treatment of depression
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram

Similar Documents

Publication Publication Date Title
JP2004527551A5 (https=)
EP1658849A3 (en) therapeutic combinations of antihypertensive and antiangiogenic agents
CA2375908A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
SE9704833D0 (sv) New formulation
ATE329608T1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
JP2022533968A5 (https=)
JP2004527551A (ja) エナンチオ純粋なエスシタロプラムの使用方法
JP2002528502A5 (https=)
JP2004537500A5 (https=)
CN102149377A (zh) 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途
JP2003504332A5 (https=)
JP2001510826A5 (https=)
JP2002522501A5 (https=)
JP2005502579A5 (https=)
CA2483002A1 (en) New pharmaceutical composition
JP2003528919A5 (https=)
SE0002729D0 (sv) Novel compound form
JP2003503453A5 (ja) ガバペンチンおよびプレガバリンを含む相乗作用組成物
JP2002503687A5 (https=)
CA2429793A1 (en) Interferon therapeutic effect enhancer
JP3567350B2 (ja) 抗脱毛症剤
JP2002535282A5 (https=)
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
JP2025503646A5 (https=)